Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? [Yahoo! Finance]
Sionna Therapeutics, Inc. (SION)
Company Research
Source: Yahoo! Finance
Superstring Capital Management initiated a new position in Sionna Therapeutics (NASDAQ:SION) , acquiring 180,593 shares in the fourth quarter. What happened According to a February 17, 2026, SEC filing , Superstring Capital Management reported a new stake in Sionna Therapeutics totaling 180,593 shares. The quarter-end value of the position stood at $7.43 million. What else to know This new position represents 3.98% of Superstring's 13F reportable AUM as of December 31, 2025. Top holdings after the filing: NASDAQ:CDTX: $18.80 million (10.1% of AUM) NASDAQ:TERN: $17.93 million (9.6% of AUM) NASDAQ:URGN: $16.82 million (9.0% of AUM) NASDAQ:COGT: $13.01 million (7.0% of AUM) NASDAQ:DVAX: $8.08 million (4.3% of AUM) As of February 13, 2026, Sionna Therapeutics shares were priced at $34.99, up about 144% over the past year and far surpassing the S&P 500's roughly 19% gain in the same period. Company overview Metric Value Price (as of Wednesday) Market capita
Show less
Read more
Impact Snapshot
Event Time:
SION
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SION alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SION alerts
High impacting Sionna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SION
News
- Hot Picks: Biotech picks target cystic fibrosis trials and rare-disease drugs [BNN Bloomberg (Canada)]BNN Bloomberg
- This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares [Yahoo! Finance]Yahoo! Finance
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by Guggenheim.MarketBeat
- Sionna Therapeutics (SION) had its "buy" rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.MarketBeat
SION
Earnings
- 11/5/25 - Beat
SION
Sec Filings
- 3/6/26 - Form 4
- 3/5/26 - Form 144
- 3/2/26 - Form S-8
- SION's page on the SEC website